Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Preview: Deciphera Pharmaceuticals's Earnings
Via Benzinga
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Where Deciphera Pharmaceuticals Stands With Analysts
Via Benzinga
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed
Via Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Why Deciphera Pharmaceuticals Stock Jumped This Week
The company's lead therapy received an FDA Breakthrough Therapy designation. 
Via The Motley Fool
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
Via Benzinga
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday. 
Via Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force. 
Via Benzinga
Why Deciphera Pharmaceuticals Stock Is Nosediving
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock. 
Via Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. 
Via Benzinga
Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.